David Hung became a director of Novocure in May 2018 and currently serves as Chief Executive Officer and a director of Nuvation Bio Inc., a biotech company. Dr. Hung was chief executive officer and a director of Axovant Sciences, Inc., a pharmaceutical company, from April 2017 to February 2018. Prior to Axovant, Dr. Hung founded and served as the president and chief executive officer, and a member of the board of directors, of Medivation, Inc., another pharmaceutical company, from its inception in 2003 through 2016 when Medivation was acquired by Pfizer. From 1998 until 2001, Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as chief scientific officer from 1998 to 1999 and as president and chief executive officer from 1999 to 2001 when ProDuct Health was acquired by Cytyc Corporation. Dr. Hung served as a director and member of the compensation committee of Opexa from 2006 to 2011, as a director of Axovant Sciences, Inc. from April 2017 to February 2018, as a director of Medivation, Inc. from 2004 to 2016 and as a director of Establishment Labs Holdings Inc. from 2016 to February 2021. He received an M.D. alpha omega alpha from the University of California, San Francisco, School of Medicine, and an A.B. summa cum laude in Biology from Harvard College.
novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma and mesothelioma. Novocure has ongoing or completed clinical trials investigating our therapy in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.